NASDAQ:CLXT

Calyxt Stock Forecast, Price & News

$3.85
-0.11 (-2.78 %)
(As of 05/11/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.59
$3.99
50-Day Range
$3.96
$7.58
52-Week Range
$3.16
$12.43
Volume375,691 shs
Average Volume280,219 shs
Market Capitalization$143.22 million
P/E RatioN/A
Dividend YieldN/A
Beta2.36
30 days | 90 days | 365 days | Advanced Chart
Receive CLXT News and Ratings via Email

Sign-up to receive the latest news and ratings for Calyxt and its competitors with MarketBeat's FREE daily newsletter.


Calyxt logo

About Calyxt

Calyxt, Inc., a technology company, focuses on delivering plant-based solutions in the United States. It engages in the development of improved digestibility alfalfa; high fiber wheat; high oleic low linolenic soybeans; winter oats; hemp; fat soybeans; and cold storable potatoes. As of March 4, 2021, the company had nine projects at Phase I stage or later in development across alfalfa, hemp, oats, soybeans, and wheat. Calyxt, Inc. has a research collaboration with NRGene, which includes the adoption of NRGene's cloud-based genomics platform to support various research projects; and a commercialization agreement with S&W Seed Company for the exclusive license of an improved quality alfalfa seed in the United States and various geographies outside the United States. The company was formerly known as Cellectis Plant Sciences, Inc. and changed its name to Calyxt, Inc. in May 2015. Calyxt, Inc. was incorporated in 2010 and is headquartered in Roseville, Minnesota. Calyxt, Inc. is a subsidiary of Cellectis S.A.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry Agricultural chemicals
Sub-IndustryN/A
Current SymbolNASDAQ:CLXT
CUSIPN/A
Phone651-683-2807
Employees59
Year FoundedN/A

Sales & Book Value

Annual Sales$7.30 million
Book Value$1.90 per share

Profitability

Net Income$-39,610,000.00
Net Margins-318.57%

Debt

Price-To-Earnings

Miscellaneous

Market Cap$143.22 million
Next Earnings Date8/4/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.29 out of 5 stars

Consumer Staples Sector

119th out of 301 stocks

Agricultural Chemicals Industry

10th out of 20 stocks

Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Calyxt (NASDAQ:CLXT) Frequently Asked Questions

Is Calyxt a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Calyxt in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Calyxt stock.
View analyst ratings for Calyxt
or view top-rated stocks.

What stocks does MarketBeat like better than Calyxt?

Wall Street analysts have given Calyxt a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Calyxt wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Calyxt's next earnings date?

Calyxt is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Calyxt
.

How were Calyxt's earnings last quarter?

Calyxt, Inc. (NASDAQ:CLXT) released its quarterly earnings results on Thursday, May, 6th. The company reported ($0.24) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.26) by $0.02. Calyxt had a negative net margin of 318.57% and a negative trailing twelve-month return on equity of 89.86%.
View Calyxt's earnings history
.

How has Calyxt's stock been impacted by Coronavirus?

Calyxt's stock was trading at $3.34 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CLXT stock has increased by 15.3% and is now trading at $3.85.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for CLXT?

5 brokerages have issued 12 month price targets for Calyxt's stock. Their forecasts range from $4.00 to $10.00. On average, they anticipate Calyxt's stock price to reach $7.50 in the next twelve months. This suggests a possible upside of 94.8% from the stock's current price.
View analysts' price targets for Calyxt
or view top-rated stocks among Wall Street analysts.

Who are Calyxt's key executives?

Calyxt's management team includes the following people:
  • Dr. Yves Joseph Ribeill, CEO & Exec. Chair of Board (Age 61, Pay $65k)
  • Mr. William F. Koschak, Chief Financial Officer (Age 52, Pay $659.15k)
  • Ms. Debra H. Frimerman, Gen. Counsel & Corp. Sec. (Age 41, Pay $452.91k)
  • Dr. Daniel F. Voytas Ph.D., Founder, Chief Science Officer & Chair of Scientific Advisory Board (Age 58)
  • Dr. Travis J. Frey Ph.D., Chief Technology Officer (Age 43)
  • Trina Lundblad, Director of Communications
  • Mr. Keith Blanks, Sr. VP of Sales & Marketing
  • Dr. Stephen M. Bravo, Chief Medical Officer
  • Simon Harnest, VP of Corp. Strategy & Fin.

Who are some of Calyxt's key competitors?

What other stocks do shareholders of Calyxt own?

When did Calyxt IPO?

(CLXT) raised $101 million in an IPO on Thursday, July 20th 2017. The company issued 6,100,000 shares at a price of $15.00-$18.00 per share. Citigroup, Credit Suisse, JefferiesWells and Fargo Securities acted as the underwriters for the IPO and BMO Capital Markets and Ladenburg Thalmann were co-managers.

What is Calyxt's stock symbol?

Calyxt trades on the NASDAQ under the ticker symbol "CLXT."

Who are Calyxt's major shareholders?

Calyxt's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Nikko Asset Management Americas Inc. (7.05%), Sumitomo Mitsui Trust Holdings Inc. (7.05%), BlackRock Inc. (2.14%) and Alliancebernstein L.P. (0.05%). Company insiders that own Calyxt stock include Andre Choulika, Anna Ewa Kozicz-Stankiewicz, Daniel F Voytas, James Blome, Manoj Sahoo, Philippe Dumont, Travis Frey and Yves J Ribeill.
View institutional ownership trends for Calyxt
.

Which institutional investors are selling Calyxt stock?

CLXT stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P.. Company insiders that have sold Calyxt company stock in the last year include Andre Choulika, Daniel F Voytas, and James Blome.
View insider buying and selling activity for Calyxt
or view top insider-selling stocks.

Which institutional investors are buying Calyxt stock?

CLXT stock was bought by a variety of institutional investors in the last quarter, including Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., and BlackRock Inc.. Company insiders that have bought Calyxt stock in the last two years include Philippe Dumont, and Travis Frey.
View insider buying and selling activity for Calyxt
or or view top insider-buying stocks.

How do I buy shares of Calyxt?

Shares of CLXT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Calyxt's stock price today?

One share of CLXT stock can currently be purchased for approximately $3.85.

How much money does Calyxt make?

Calyxt has a market capitalization of $143.22 million and generates $7.30 million in revenue each year. The company earns $-39,610,000.00 in net income (profit) each year or ($1.21) on an earnings per share basis.

How many employees does Calyxt have?

Calyxt employs 59 workers across the globe.

What is Calyxt's official website?

The official website for Calyxt is www.calyxt.com.

Where are Calyxt's headquarters?

Calyxt is headquartered at 2800 MOUNT RIDGE ROAD, ROSEVILLE MN, 55113.

How can I contact Calyxt?

Calyxt's mailing address is 2800 MOUNT RIDGE ROAD, ROSEVILLE MN, 55113. The company can be reached via phone at 651-683-2807 or via email at [email protected]


This page was last updated on 5/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.